Conatus Pharmaceuticals Stock Price - CNAT

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Conatus Pharmaceuticals Inc CNAT NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.0092 2.72% 0.3477 0.355 0.3315 0.34 0.3385 15:49:53
Bid Price Ask Price Spread Spread % News
0.3436 0.3477 0.0041 1.18% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
365 223,356 $ 0.3445275 $ 76,952 869,655 0.25 - 5.89
Last Trade Time Type Quantity Stock Price Currency
15:50:47 100 $ 0.3477 USD

Conatus Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 11.54M 33.17M $ -18.01M -0.59 -0.93 32.98M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 0.60%

more financials information »

Conatus Pharmaceuticals News

Loading Messages....

Latest CNAT Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CNAT Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.3350.40440.3250.36449791,089,9940.01273.79%
1 Month0.32920.40440.30420.3426497647,1690.01855.62%
3 Months0.320.43670.25010.3458253710,7790.02778.66%
6 Months0.751.070.250.4139552801,203-0.4023-53.64%
1 Year4.395.890.251.36890,033-4.04-92.08%
3 Years1.949.400.253.78781,997-1.59-82.08%
5 Years7.2511.740.254.07642,461-6.90-95.2%

Conatus Pharmaceuticals Description

Conatus Pharmaceuticals Inc is a biotechnology company. It focuses on the development and commercialization of novel medicines to treat liver disease. The company is developing emricasan, an orally active pan-caspase protease inhibitor, for the treatment of patients with the chronic liver disease.

Your Recent History
Conatus Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.